title: Anthracycline in colorectal carcinoma: an in vitro short-term assay to predict drug sensitivity. Preliminary results.
abstract: The chemosensitivity of 26 non-pretreated colorectal carcinomas (primary tumors and/or colorectal metastases) was studied by an in vitro antimetabolic assay, which evaluates the interference of drugs on the incorporation of 3H-thymidine and 3H-uridine in short-term cultures of human tumors. Our results correlate with the response rate obtained in clinical studies with monochemotherapy and justify the possibility of a future prospective study using individually tailored chemotherapy regimens. Doxorubicin-analogues, with an overall in vitro efficacy in 16.0% and 14.3% for 4-epidoxorubicin (epi-DX) and 4-deoxydoxorubicin (deo-DX), respectively, seem to deserve a modest role in the treatment of colorectal cancer, provided that a careful selection of patients is performed. Variability in anthracycline activity is indeed evident, also in our study, in relation to the different neoplastic picture of the various patients.
authors.forename: P
authors.initials: P
authors.lastname: Seminara
authors.forename: F
authors.initials: F
authors.lastname: Franchi
authors.forename: M
authors.initials: M
authors.lastname: Mulieri
authors.forename: R
authors.initials: R
authors.lastname: D'Amelio
authors.forename: G
authors.initials: G
authors.lastname: Codacci Pisanelli
authors.forename: T
authors.initials: T
authors.lastname: Aronne
authors.forename: D
authors.initials: D
authors.lastname: Manfredi
mesh_terms: D003110:Colonic Neoplasms / Q000473:pathology*; D004273:DNA, Neoplasm / Q000032:analysis; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D004351:Drug Resistance; D015251:Epirubicin; D006801:Humans; D066298:In Vitro Techniques; D008113:Liver Neoplasms / Q000473:pathology / Q000556:secondary*; D012334:RNA, Neoplasm / Q000032:analysis; D012004:Rectal Neoplasms / Q000473:pathology*
chemical_list: D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D015251:Epirubicin; D004317:Doxorubicin; C030851:esorubicin